Significance {#sec1}
============

**Several types of cancer are associated with severe pain, which markedly reduces the quality of life in patients. Molecular mechanisms underlying cancer pain remain poorly understood. Despite close proximity between sensory nerves and blood vessels in tumor-affected tissues, neither mutual interactions nor angiogenic molecules have been studied in the context of cancer pain. Here, we report that VEGF signaling is operational in nerves as well as blood vessels at the tumor-nerve interface. Perturbing expression, activation, or signaling of VEGFR1, but not of VEGFR2, in peripheral sensory nerves disrupts attenuated cancer-induced pain and tumor-induced remodeling of nerves in mice in vivo. Thus, drugs targeting VEGFR1 as well as VEGF family ligands hold potential in treating cancer pain.**

Introduction {#sec2}
============

Pain is one of the most severe and common symptoms of a variety of cancers and constitutes a primary determinant of the poor quality of life in cancer patients ([@bib24]). Bone metastases and pancreatic ductal adeno carcinoma (PDAC) are among the most painful forms of cancer-associated pain. Apart from inflammatory and neuropathic components, bilateral interactions between tumor cells and nerve cells constitute the cornerstone of cancer ([@bib8; @bib24; @bib27]). Therefore, molecular mechanisms underlying tumor-nerve interactions hold promise for understanding and treating cancer-associated pain.

Although nerves and blood vessels share physical proximity and wide set of signaling systems, regulators of vascular remodeling have not received attention in the context of tumor-associated pain so far. Vascular Endothelial Growth Factor (VEGF) family of factors-mediated signaling is not only crucial in vascular development during embryogenesis and angiogenesis ([@bib26]), but also operational in a variety of non-endothelial cells, including developing neurons.

VEGF family ligands can bind to and signal via two receptor tyrosine kinases, namely, VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2), which are highly homologous in overall structure, but have distinct biological functions in vivo ([@bib12]). So far, VEGFR2 has been implicated in all aspects of physiological and pathological angiogenesis, e.g., in tumor angiogenesis, macular degeneration of the retina, whereas VEGFR1 has been mostly thought to act primarily as a decoy receptor that indirectly limits VEGFR2 activation ([@bib12; @bib16]). However, there is also evidence for VEGFR1 in transferring biological signals and enhancing the activity of VEGFR2 in vivo ([@bib26]), indicating that the relative contributions of VEGFR1 and VEGFR2 can vary in a context-dependent manner. Apart from VEGF-A, other VEGF family ligands, such as placental growth factor-2 (PLGF-2) and VEGF-B, are also released in the tumor microenvironment ([@bib14]).

This study investigates biological mechanisms and therapeutic potential of VEGF family of factors and their signaling mechanisms in cancer pain.

Results {#sec3}
=======

VEGFRs Are Expressed in Peripheral Sensory Nerves and Their Cell Bodies in Dorsal Root Ganglia {#sec3.1}
----------------------------------------------------------------------------------------------

As a first step toward characterizing a potential role for the VEGF signaling axis in the tumor-neuro-vascular link, we analyzed the expression of VEGFRs in mouse tissues using antibodies that have been tested for specificity in previous studies ([@bib29]) and in RNA interference experiments described below.

Confocal dual immunofluorescence analysis on sections of mouse dorsal root ganglia (DRG), where the somata of sensory nerves reside, broadly revealed immunoreactivity for anti-VEGFR1 distributed over the whole cell body of sensory neurons, whereas anti-VEGFR2 immunoreactivity was primarily localized to the nucleus ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). All classes of sensory neurons, including peptidergic nociceptive (CGRP), non-peptidergic nociceptive (Isolectin-B4-binding), and tactile-sensitive neurons expressing Neurofilament 200 (NF200), broadly expressed VEGFR1 and VEGFR2 ([Figures 1](#fig1){ref-type="fig"}A, 1B, [S1](#mmc1){ref-type="supplementary-material"}B, and S1C).

Western blot analyses on lysates of mouse DRG revealed a band of the expected size for VEGFR1 at 180 kDa ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}D), but not bands corresponding to soluble (short-form) VEGFR1. The unglycosylated form of VEGFR2 at 150 kDa ([@bib17]) was detected in DRG lysates ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}E). Expression of VEGFR1 and VEGFR2 in neuron-enriched cultured mouse DRG cultures was confirmed via western blotting as well as reverse transcriptase PCR analysis ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}F). Anti-VEGFR1 immunoreactivity was also observed on sensory axons in DRG cultures ([Figure S1](#mmc1){ref-type="supplementary-material"}G) as well as peripheral nerves in the mouse hind paw skin in vivo ([Figure 1](#fig1){ref-type="fig"}D).

In Vivo Modulation of Nociception by VEGF-A {#sec3.2}
-------------------------------------------

To address potential function, we simulated VEGF receptor activation via unilateral intraplantar injections of VEGF-A in the hind paw of mice at doses comparable to concentrations of VEGF-A reported in the tumor microenvironment ([@bib21]) and to doses of other nociceptive mediators studied previously ([@bib27]). Although VEGF-A did not evoke spontaneous pain behavior, mice showed a significant hypersensitivity to graded von Frey mechanical stimuli and infrared noxious heat applied to the hind paw within 30 min of VEGF-A injection, as compared with saline-treated mice ([Figures 1](#fig1){ref-type="fig"}E--1H). VEGF-A-induced hypersensitivity was dose dependent, starting with doses as low as 1--10 pg and reaching maximal values at 100 pg, and lasted for up to 24 hr after a single injection ([Figures 1](#fig1){ref-type="fig"}F and 1H).

Direct Modulation of Sensory Nerve Function by VEGF-A {#sec3.3}
-----------------------------------------------------

Doses of VEGF-A that elicited marked nociceptive hyperexcitability led to neither any obvious signs of vasodilation nor significant changes in neurogenic inflammation ([Figure 1](#fig1){ref-type="fig"}I), in contrast to the positive control histamine.

Furthermore, electrophysiological single-fiber recordings on an in vitro preparation of paw skin with attached saphenous nerve perfused in Ringer solution, single Aδ-nociceptive fibers exposed to VEGF-A (1 to 200 ng/ml for 30 min) demonstrated significantly higher discharge rates in response to graded mechanical stimuli than fibers exposed to the vehicle ([Figure 1](#fig1){ref-type="fig"}J), thereby demonstrating that VEGF-A directly sensitizes nociceptive axons.

VEGF-A Mediates Its Pronociceptive Effects via VEGFR1 {#sec3.4}
-----------------------------------------------------

Mechanical and thermal hyperalgesia evoked by intraplantar VEGF-A was blocked by intraplantar pretreatment with a neutralizing antibody against the extracellular domain of VEGFR1, but not by a VEGFR2-neutralizing antibody or control IgG ([Figures 2](#fig2){ref-type="fig"}A and 2B). Consistently, VEGF-A failed to induce mechanical sensitization of Aδ-nociceptors in electrophysiological recordings when pretreated with VEGFR1 antibody ([Figure 2](#fig2){ref-type="fig"}C). Furthermore, mice selectively lacking the tyrosine kinase signaling domain of VEGFR1 (VEGFR1-Tk^−/−^; [@bib16]) did not develop mechanical and thermal sensitization upon intraplantar VEGF-A injection ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}A). Thus, VEGFR1 acting via tyrosine kinase signaling, but not VEGFR2, is required for sensitization of nociceptors by VEGF-A.

Furthermore, intraplantar injection of neutralizing antibodies directed against NRP-1 or NRP-2, which function as VEGFR co-receptors in some systems ([@bib26]), did not inhibit VEGF-induced nociceptive sensitization ([Figure 2](#fig2){ref-type="fig"}E), indicating that these potential co-receptors do not contribute to VEGF-induced nociceptive sensitization.

Contributions of Other Ligands of the VEGF Family to Nociceptive Sensitization {#sec3.5}
------------------------------------------------------------------------------

Intraplantar application of VEGF-E, a specific agonist at VEGFR2 ([@bib12]) ([Figure 2](#fig2){ref-type="fig"}A), at doses up to 100 ng, did not evoke any changes in mechanical or thermal sensitivity as compared with saline injection ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}B). In contrast, intraplantar injection of VEGF-B or PLGF-2, which activate VEGFR1 but not VEGFR2 ([@bib14]), evoked dose-dependent mechanical and thermal hypersensitivity ([Figures 2](#fig2){ref-type="fig"}G, 2H, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D), with PLGF-2 being efficacious at doses as low as 1 pg. Thus, diverse peripheral VEGFR1-specific agonists can induce nociceptive hypersensitivity.

Signaling Mediators of VEGFR1 and Their Contribution to Nociceptive Hypersensitivity {#sec3.6}
------------------------------------------------------------------------------------

VEGFRs activate diverse intracellular signaling targets ([Figure 3](#fig3){ref-type="fig"}A; [@bib26]). In neuron-enriched DRG cultures, VEGF-A induced phosphorylation of ERK1/2 ([Figure 3](#fig3){ref-type="fig"}B), indicating that VEGFRs expressed on sensory neurons are functionally active. To test mechanistic contributions, we administered diverse pharmacological inhibitors intraplantar, at doses reported to be specific in previous in vivo studies ([@bib23]). Neither the vehicle (2% DMSO) nor any of the inhibitors affected nociceptive sensitivity when given in the absence of VEGF treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Inhibition of phospholipase C gamma (PLCγ) with U71322, the nitric oxide synthase (NOS) with L-NAME, phosphotidyl inositol 3-kinase (PI3K) with LY294002, or the tyrosine kinase Src with PP2 either completely abolished or strongly attenuated mechanical and thermal hypersensitivity induced by VEGF-A given 30-min post-inhibitor treatment ([Figure 3](#fig3){ref-type="fig"}C). PP3, the inactive analog of PP2, did not affect VEGF-A-induced hypersensitivity ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Inhibition of MEK-dependent activation of ERK1/2 via the MEK inhibitor PD98059 significantly attenuated VEGF-A-induced mechanical hypersensitivity, but did not affect VEGF-A-induced thermal hyperalgesia ([Figure 3](#fig3){ref-type="fig"}C; p = 0.322). Finally, inhibition of the p38 MAPK pathway using SB203580 affected neither VEGF-A-induced mechanical hypersensitivity nor thermal hyperalgesia ([Figure 3](#fig3){ref-type="fig"}C; p = 0.75).

Moreover, we observed identical modulation of PLGF-2-induced hyperalgesia with the aforementioned inhibitors as with VEGF-A-induced hyperalgesia ([Figure S3](#mmc1){ref-type="supplementary-material"}C), indicating common VEGFR1-mediated mechanisms.

We then addressed whether the diverse pathways involved in VEGF-A/PLGF-2-dependent hypersensitivity all function downstream of VEGFR1 or act in parallel to VEGFR1. Doses of inhibitors that only partially inhibit VEGF-induced hypersensitivity were identified in experiments shown in [Figures 3](#fig3){ref-type="fig"}D, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E. We observed that half-maximal doses of the inhibitors of PLCγ, PI3K, or Src kinase, which represent the initiation points of three distinct VEGFR1-activated pathways, did not add to the pain-alleviating function of partial VEGFR1 blockade ([Figures 3](#fig3){ref-type="fig"}D, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E) suggesting serial, rather than parallel, relationship of these signaling cascades with VEGFR1.

Consistent with our observations with NO blockade (above), we observed that mice lacking *Prkg1*, a key target of the NO-cGMP pathway, specifically in peripheral nociceptors ([@bib22]), did not develop mechanical and thermal hypersensitivity with VEGF-A ([Figure 3](#fig3){ref-type="fig"}E). We also found several lines of evidence linking VEGF-A signaling to modulation of TRPV1, the key final effector of thermal hyperalgesia ([@bib5]). First, VEGF-A failed to evoke thermal hyperalgesia in mice genetically lacking *Trpv1*, although VEGF-A-induced mechanical hypersensitivity was fully preserved ([Figure 3](#fig3){ref-type="fig"}F). Second, Src, which is known to phosphorylate TRPV1 and increase its membrane targeting ([@bib5]), was rapidly and significantly phosphorylated in cultured sensory neurons upon treatment with VEGF-A ([Figure 3](#fig3){ref-type="fig"}G). Third, in mice injected intraplantar with VEGF-A, the quantity of TRPV1, which could be pulled down from membranes of the distal sciatic nerve segments, was significantly increased as compared with vehicle-injected mice with a time course consistent with VEGF-A-induced thermal hyperalgesia ([Figure 3](#fig3){ref-type="fig"}H). These results indicate that VEGF promotes the trafficking and surface expression of TRPV1 in the sciatic nerve and thereby provides a mechanistic basis for thermal hyperalgesia. On the other hand, TRPA1 and P2X3 have been implicated in mechanical hypersensitivity ([@bib7; @bib19]). VEGF-A-induced mechanical hypersensitivity was not affected by A317491 at the concentration reported to be efficacious in blocking P2X3 ([@bib19]) ([Figure S3](#mmc1){ref-type="supplementary-material"}F), but was abolished in mice lacking *Trpa1* ([Figure 3](#fig3){ref-type="fig"}I). Thus, modulation of ion channels, such as TRPV1 and TRPA1, by VEGFR1-activated signaling pathways in peripheral neurons can account for nociceptive sensitization evoked by VEGFR1 agonists.

Altered Expression of VEGFR1 in Sensory Nerves of Mice Implanted with Osteolytic Sarcoma and Its Specific Contribution to Cancer Pain {#sec3.7}
-------------------------------------------------------------------------------------------------------------------------------------

To study tumor-associated pain, we first utilized a model based on injection of osteolytic sarcoma cells into the intermedullary space of the calcaneus bone of the mouse heel, which reflects pain caused by primary sensitization of nerves in the vicinity of the calcaneus bone and which has been reported to closely mimic tumor-induced sensory alterations in humans ([@bib8; @bib31]). Western blot analysis showed that VEGFR1, but not VEGFR2, was significantly upregulated in the lysates of ipsilateral L3--L4 lumbar DRGs isolated from tumor-bearing mice as compared with sham-treated animals ([Figure 4](#fig4){ref-type="fig"}A); no upregulation was observed in contralateral DRGs of tumor-bearing mice ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Furthermore, injection of non-tumorigenic cells, such as MEFs, in the calcaneus cavity neither led to an induction of VEGFR1 in the DRG ([Figure S4](#mmc1){ref-type="supplementary-material"}B) nor elicited nociceptive hypersensitivity ([Figure S4](#mmc1){ref-type="supplementary-material"}C), indicating specificity. Interestingly, TRPV1, which mediates VEGF-A-induced thermal hyperalgesia, ([Figure 3](#fig3){ref-type="fig"}F) was found to be also upregulated in DRGs of cancer-bearing mice ([Figure S4](#mmc1){ref-type="supplementary-material"}D).

Furthermore, we observed that immunoreactivity for anti-VEGFR1 was significantly increased in paw sections derived from tumor-bearing mice as compared with sham-treated mice, including PGP9.5-positive peripheral nerves ([Figure 4](#fig4){ref-type="fig"}B).

A key functional contribution of VEGFR1 expressed in DRG neurons to pain was observed in experiments involving specific lentiviral knockdown of VEGFR1 expression in L3--L4 DRGs ([Figure 4](#fig4){ref-type="fig"}C; infection rate, 76% ± 5.3% of all DRG neurons shown in [Figure 4](#fig4){ref-type="fig"}D; lack of infection of blood vessels in the DRG confirmed via co-staining with anti-CD31 in [Figure S4](#mmc1){ref-type="supplementary-material"}E). The efficacy of VEGFR1 downregulation in ipsilateral L3--L4 DRGs was ascertained by western blotting ([Figure 4](#fig4){ref-type="fig"}E) and behavioral experiments showing a marked reduction in VEGF-A-induced mechanical and thermal hypersensitivity ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Importantly, as compared with mice expressing non-targeting shRNA, development of tumor-induced mechanical hypersensitivity was significantly and markedly attenuated in mice expressing VEGFR1-shRNA ([Figure 4](#fig4){ref-type="fig"}F). Furthermore, tumor-induced structural changes of nerves in the paw skin overlaying the growing tumor, such as hypertrophy and epidermal sprouting ([@bib8; @bib27]), were evident in control shRNA-expressing mice, but not in VEGFR1-shRNA-expressing mice ([Figures 4](#fig4){ref-type="fig"}G and 4H). These observed differences between tumor pain and nerve remodeling did not result from any differences in tumor growth ([Figure S4](#mmc1){ref-type="supplementary-material"}G).

Evidence from Genetic Models and an Independent Cancer Pain Model {#sec3.8}
-----------------------------------------------------------------

To further obtain evidence from genetic models and to specifically delineate the contribution of VEGFR1 expressed in nociceptive neurons of the DRG, we generated a line of transgenic mice conditionally lacking VEGFR1 in nociceptive neurons by mating *Vegfr1*^*fl/fl*^ mice ([@bib2]) with SNS-Cre mice ([@bib1]) (SNS-*Vegfr1*^−/−^ mice). Western blot analysis ([Figure 5](#fig5){ref-type="fig"}A) confirmed a decrease in DRG expression of VEGFR1 (55% ± 2.8% of the value in *Vegfr1*^*fl/fl*^ mice). Intraplantar VEGF-A-induced mechanical and thermal hypersensitivity was nearly entirely lost in SNS-*Vegfr1*^−/−^ mice as compared with their WT littermates, indicating a requirement for VEGFR1 expressed in peripheral nociceptors ([Figures 5](#fig5){ref-type="fig"}B and 5C).

The C57Bl6 genetic background of these genetically modified mice necessitated employing a model of cancer pain involving isogenic tumor cells. We therefore employed a previously described model involving subcutaneous injection of isogenic LL2 lung carcinoma cells, which results in behavioral, structural, and functional changes similar to the above-described calcaneus model ([@bib11]). LL2 carcinoma-induced mechanical hypersensitivity ([Figure 5](#fig5){ref-type="fig"}D) and tumor-induced remodeling of neighboring PGP9.5-positive nerves ([Figures 5](#fig5){ref-type="fig"}E and 5F) were significantly decreased in SNS-*Vegfr1*^−/−^ mice as compared with *Vegfr1*^*fl/fl*^ mice, without any observable difference in tumor growth across genotypes ([Figure 5](#fig5){ref-type="fig"}G). Moreover, tumor-bearing VEGFR1-Tk^−/−^ mice showed a significantly attenuated hypersensitivity as compared with tumor-bearing WT littermates without showing changes in tumor growth ([Figures 5](#fig5){ref-type="fig"}H and 5I).

VEGFR1 Expression in Sensory Nerves in Human Cancer with Pain and Its Contribution to Pain in a Mouse Model of Pancreatic Ductal Adenocarcinoma {#sec3.9}
-----------------------------------------------------------------------------------------------------------------------------------------------

Given the abundance of VEGF-A and PLGF-2 in the tumor milieu of human pancreatic carcinoma ([@bib10]), we analyzed pancreatic biopsies derived from human pancreatic ductal adenocarcinoma (PDAC) patients and observed anti-VEGFR1 immunoreactivity not only in blood vessels, but also in 66.3% ± 6.5% of PGP9.5-positive peripheral nerves ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). Furthermore, anti-VEGFR1 immunoreactivity was observed in more than 70% of each of the following fiber types analyzed from 21 sections derived from 13 PDAC biopsies: CGRP-positive nociceptive nerves, NF200-positive large-diameter (tactile) sensory nerves, TH-expressing sympathetic nerves, and a subpopulation of tactile sensory fibers and ChAT-expressing parasympathetic nerves ([Figures 6](#fig6){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}B).

Importantly, nerve fibers showed a significant increase in the intensity as well as the area of anti-VEGFR1 immunoreactivity in biopsies of PDAC patients as compared with healthy donors ([Figures 6](#fig6){ref-type="fig"}C and 6D), which was significantly proportional to perceived pain intensity in PDAC patients (severe, moderate, or mild) based upon subjective pain ratings ([Figures 6](#fig6){ref-type="fig"}E and 6F).

We then undertook functional experiments to address the role of VEGFR1 in PDAC-related pain. First, because VEGFR1 was observed to be broadly expressed in the DRG, including non-nociceptive and nociceptive neurons, we generated transgenic mice conditionally lacking VEGFR1 specifically in all neurons of the DRG (Adv-*Vegfr1*^*−*/*−*^ mice) by using Advillin-Cre mice ([@bib33]). Adv-*Vegfr1*^*−*/*−*^ mice were studied in western blot analysis ([Figure 6](#fig6){ref-type="fig"}G; 69% ± 3.5% loss over control mice) and showed a complete loss of mechanical and thermal sensitization with intraplantar VEGF-A ([Figure 6](#fig6){ref-type="fig"}H). Second, we established behavioral analysis of pain associated with PDAC by employing a model based on orthotopic implantation of mouse PanCO2 PDAC tumor cells or vehicle (sham) in the pancreas of C57Bl6 mice ([@bib32]). Upon testing sensitivity to abdominal application of low force-von Frey hairs, we observed that post-operative pain was comparable across PanCO2-injected Adv-*Vegfr1*^*−*/*−*^ mice and control littermates (also evident in sham-injected mice; data not shown), but tumor-induced mechanical hypersensitivity starting from day 13 (specific to PanCO2-injected mice) was significantly reduced in Adv-*Vegfr1*^*−*/*−*^ mice as compared with control littermates ([Figure 6](#fig6){ref-type="fig"}I). Importantly, SNS-*Vegfr1*^*−*/*−*^ mice demonstrated a similar degree of attenuation of tumor-induced nociceptive hypersensitivity as Adv-*Vegfr1*^*−*/*−*^ mice ([Figure 6](#fig6){ref-type="fig"}I), indicating that VEGFR1 expressed on nociceptive neurons can largely account for the key role observed for VEGFR1 to tumor pain. Pancreatic tumor size was not significantly different across genotypes ([Figure 6](#fig6){ref-type="fig"}J).

Availability of Diverse VEGFR1 Ligands in the Context of Cancer Pain and Their Functional Contributions {#sec3.10}
-------------------------------------------------------------------------------------------------------

ELISA-based analysis demonstrated a high level of availability of VEGF-A as well as PLGF-2 in paw tissue surrounding the tumor, including sensitized skin, in the calcaneus osteolytic sarcoma implantation model ([Figure 7](#fig7){ref-type="fig"}A). Injection of specific function-blocking antibodies directed against VEGF-A or PLGF-2 in the vicinity of the tumor led to a strong reduction in tumor-associated mechanical hypersensitivity ([Figure 7](#fig7){ref-type="fig"}B). Anti-VEGF-A, but not anti-PLGF-2, significantly reduced tumor growth at the doses tested ([Figure 7](#fig7){ref-type="fig"}B). Moreover, an antibody neutralizing VEGF-B significantly reduced tumor-induced hypersensitivity, but to a lesser degree than anti-VEGF-A or anti-PLGF-2 ([Figure S6](#mmc1){ref-type="supplementary-material"}A), without affecting tumor growth ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Thus, diverse VEGFR1 ligands are locally available in the tumor milieu and contribute collectively to tumor-induced hypersensitivity.

We further employed two biological tools to bind and sequester VEGFR1 ligands and/or prevent them from binding to VEGFR1. First, in comparison to injection of a control Fc protein, local injection of soluble form of VEGFR1 lacking the C terminus and the kinase domain (sFlt1) ([@bib12]) blocked VEGF-A-induced hyperalgesia ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D), significantly attenuated tumor-associated hypersensitivity ([Figure 7](#fig7){ref-type="fig"}C), and reduced tumor growth to a small but significant extent ([Figure 7](#fig7){ref-type="fig"}C). Second, we employed a small anti-VEGFR1 hexapeptide (GNQWFI, anti-Flt1 peptide), which prevents binding of all ligands to the extracellular domain of VEGFR1 ([@bib3]). However, because this peptide has only been used in a few in vivo studies so far ([@bib3]), we validated in vivo efficacy by testing impact on VEGFR1 activation judged via tyrosine phosphorylation on VEGFR1 on position 1213, which was significantly enhanced in tumor-bearing paw compared with sham-treated paw ([Figure 7](#fig7){ref-type="fig"}D). Upon administration of a single intraplantar injection of the anti-Flt1 peptide at a dose of 25 μg, tumor-associated tyrosine phosphorylation of VEGFR1 was significantly attenuated for 24 hr ([Figure 7](#fig7){ref-type="fig"}D). This dose of the anti-Flt1 peptide blocked intraplantar VEGF-A-induced nociceptive hypersensitivity ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F) and also significantly attenuated tumor-associated mechanical hypersensitivity when given over multiple time points ([Figure 7](#fig7){ref-type="fig"}E). These differences did not arise from differences in tumor growth between groups ([Figure 7](#fig7){ref-type="fig"}E). Furthermore, infiltration of GR-1-positive neutrophils in the tumor vicinity was not significantly different across the above groups ([Figure S6](#mmc1){ref-type="supplementary-material"}G).

Effects of Local Immunological Blockade of VEGFR1 or VEGFR2 Signaling on Cancer Pain and Nerve Remodeling {#sec3.11}
---------------------------------------------------------------------------------------------------------

Given their growing therapeutic potential in cancer treatment, we tested immunologicals for efficacy in repressing VEGFR1-mediated nociceptive hypersensitivity and tumor-associated pain as well as the accompanying nerve remodeling.

First, in the calcaneus osteolytic sarcoma implantation model, local administration of anti-VEGFR1, but not anti-VEGFR2 or control IgG, in the vicinity of the tumor on days 1, 3, 5, 7, 9, 11, and 13 post-tumor cell implantation significantly blocked tumor-induced mechanical hypersensitivity ([Figure 8](#fig8){ref-type="fig"}A) and significantly attenuated tumor-associated sprouting and hypertrophy of PGP9.5-positive nerve fibers in the epidermis ([Figure 8](#fig8){ref-type="fig"}B). No differences were observed with respect to local tumor growth or local inflammation with anti-VEGFR1 at the dose applied ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7C). Interestingly, however, in tumor-bearing mice, locally administered anti-VEGFR2 suppressed tumor angiogenesis to a much stronger extent than anti-VEGFR1, as compared with mice that received control IgG ([Figure S7](#mmc1){ref-type="supplementary-material"}D), indicating that VEGFR1 and VEGFR2 mediate differential aspects of remodeling in the tumor-nerve-blood vessel milieu.

Efficacy of Systemically Administered Anti-VEGFR Immunologicals in a Model of Cancer-Induced Bone Pain as a Potential Therapeutic Strategy {#sec3.12}
------------------------------------------------------------------------------------------------------------------------------------------

Finally, we endeavored to test the efficacy of systemically administered immunologicals using a clinically relevant model that simulates pain induced by metastases in large skeletal bones in cancer patients ([@bib6; @bib24]). Upon unilateral implantation of mammary carcinoma cells in the intermedullary cavity of mouse femur bone, mice not only show nociceptive hypersensitivity in the ipsilateral hind paw (secondary hyperalgesia), but also signs of spontaneous ongoing pain, such as lifting or flicking of the affected limb and altered gait ([@bib6; @bib24]; [Movies S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}). High-quality function-blocking antibodies against VEGFR1 (MF-1) or VEGFR2 (DC101), which have been validated in vivo previously upon intraperitoneal delivery in mice ([@bib9; @bib13]), were administered at every 3 days until day 29 post-tumor cell implantation.

Systemically delivered MF-1 strongly attenuated the development of nociceptive hypersensitivity to von Frey force applied to the ipsilateral hind paw ([Figure 8](#fig8){ref-type="fig"}C) as compared with control IgG or DC101 application. Similar results were observed with respect to tumor-induced spontaneous nocifensive pain behavior ([Figure 8](#fig8){ref-type="fig"}D; [Movies S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}). At late stages only (30-days post-tumor implantation), a partial suppression of nociceptive hypersensitivity or spontaneous pain behavior was observed with the systemically delivered DC101.

Furthermore, mice receiving systemic treatment with the MF1, but not DC101 or control IgG, showed a marked reduction in bone metastases-induced sprouting of periosteal nerves ([Figure 8](#fig8){ref-type="fig"}E). Both clones significantly reduced the growth rate of mammary carcinoma cells in mice upon systemic delivery ([Figure S7](#mmc1){ref-type="supplementary-material"}E); however, DC101 suppressed tumor growth to a higher extent than MF1, indicating again a mechanistic dichotomy of VEGFR2 and VEGFR1 in the modulation of tumor growth and nociceptive sensitization in cancer pain.

Discussion {#sec4}
==========

VEGF signaling has already gained major significance in the pathophysiology and therapy of cancer; this study extends its functional and therapeutic repertoire beyond tumor angiogenesis and metastases to the avenue of cancer pain by acting at the interface between tumor cells, blood vessels, and nerves to regulate pain sensitivity via functional and structural modulation. We present several converging lines of evidence showing that peripherally acting VEGF ligands induce nociceptive sensitization via direct effects on peripheral nerves, rather than non-neuronal modulation, and that the contribution of nociceptors is paramount.

Our analyses indicate that VEGFR1 activation in sensory neurons triggers both functional and structural remodeling. VEGFR1 activated diverse kinases, such as PLCγ, PI3K, and Src kinase, that sensitize transducers of heat, pressure, and chemical stimuli in nociceptive terminals, such as TRPV1 and TRPA1, as well as amplifiers of afferent excitability, such as Na~v~1.8 ([@bib5; @bib18]). Our observation that VEGFR1 modulates TRPV1 function via Src and promotes its trafficking in peripheral nerves is interesting because TRPV1 senses local acidosis and algogens, such as eicosanoids and lipids, which are abundant in the tumor environment ([@bib24]).

Our findings on the role of VEGFR1 in cancer-related structural remodeling of nerves and its upregulation in sensory nerves within the tumor milieu in mouse models and PDAC patients indicates a strong link between VEGF signaling in sensory nerves, structural remodeling, and pain; however, a causal relationship between nerve sprouting and pain in cancer cannot yet be derived. Of note, VEGF-mediated signaling converges with that of NGF, another major player in nerve remodeling ([@bib25]), on common intracellular effectors, e.g., the PI3K-Akt pathway.

Remarkably, our results suggest a functional dichotomy of the two main lines of VEGF signaling in sensory nerves and blood vessels. Although VEGFR2 regulates tumor angiogenesis ([@bib12]), it does not contribute to sensitization of nerves: this may be accounted for by the observed nuclear localization for VEGFR2 in sensory neurons, the higher level of distribution of VEGFR1 at the cell surface of sensory neurons and the 10-fold higher affinity of VEGF-A for VEGFR1 over VEGFR2.

The efficacy of targeting PLGF-2 in cancer therapy is a much debated topic of acute interest and high relevance in the cancer field (e.g., [@bib4; @bib30]). Our observation that PLGF-2 is even more potent and efficacious than VEGF-A in inducing nociceptive hypersensitivity may stem from proposed differences in the VEGFR1 binding/activation mode between these agonists ([@bib9]). Furthermore, on the background of reports on synergistic activation of VEGFR1 by PLGF-2 and VEGF-A in angiogenesis and plasma extravasation ([@bib9]), our results suggest that a co-release of these factors in the tumor microenvironment may cooperate in evoking exaggerated pain sensitivity.

Administration of Bevacizumab, a humanized monoclonal immunological sequestering VEGF-A, enhances the quality of life in cancer patients ([@bib15; @bib20]), which would be generally consistent with this study since pain is an important parameter for quality of life in cancer patients. Our results therefore suggest that pain should be directly and objectively tested as a clinical end point in clinical studies involving VEGF-targeted therapies in cancer patients. Furthermore, given our results showing roles for VEGF-A, PLGF-2, and VEGF-B in bone metastatic pain, we suggest that targeting individual ligands may be less efficacious than targeting the receptor (VEGFR1) they converge upon. Moreover, our results on the efficacy of locally applied small anti-Flt1 peptide in tumor pain models provide scope for limiting side effects attributed to immunologicals and global intervention in VEGF signaling.

Taken together, our findings from several animal models of cancer pain, human cancer material, and mechanistic analyses indicate therapeutic potential for VEGFR1-modifying drugs in cancer pain and suggest that combined targeting of VEGFR1 and VEGFR2 may enable modulation of distinct aspects of cancer at the tumor-neuro-vascular interface.

Experimental Procedures {#sec5}
=======================

Sensory-Neuron-Specific Knockout Mice {#sec5.1}
-------------------------------------

Mice lacking VEGFR1 in a sensory neuron-specific manner were generated by mating mice carrying floxed alleles of the *Flt1* (vegfr1) gene ([@bib2]) with mice expressing the Cre recombinase selectively in nociceptors (SNS-Cre; [@bib1]) or with mice expressing the Cre recombinase selectively in all neurons of the DRG (Advillin-Cre; [@bib33]).

Antibodies Used for Immunohistochemistry and Western Blotting {#sec5.4}
-------------------------------------------------------------

The following are used for immunohistochemistry on mouse paw skin: PGP9.5 (1:1000, Ultraclone), and on human pancreatic biopsies: (1) anti-PGP9.5 (1:1000; Ultraclone), (2) anti-VEGFR1 (1:200, \#AF321, R&D Systems), (3) anti-VEGFR2 (1:200; MAB3571; R&D Systems), (4) anti-choline acetyl transferase (1:400; Neuromics), (5) anti-tyrosine hydroxylase (\#22941; Immunostar), (6) anti-CGRP (1:300; 24112; Immunostar), (7) anti-neurofilament-200 antibody (1:500, \#N4142; Sigma Aldrich), and (8) anti-CD31 (clone JC70A, \#M0823; DAKO Deutschland GmBH).

The following are used for immunofluorescence analysis on mouse DRGs: anti-VEGFR1 (1:100; MAB471; R&D Systems); anti-VEGFR2 (1:100; sc-505; Santa Cruz Biotechnology SCBT), anti-CGRP (1:300; 24112; Immunostar) and biotinylated IB~4~ (1:200; B-1205; Vector), anti-neurofilament-200 antibody (1:500, \#N2912, \#N4142; Sigma Aldrich), anti-CD31 (1:500, \#550274; BD PharMingen) (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}); western blotting: anti-VEGFR1 (1:1000; \#1301-1; Epitomics), anti-VEGFR2 (1:1000; sc-505; SCBT), a phospho-VEGFR1 (Tyr1213) antibody (07-758; Merck Millipore), anti-Src and anti-phospho-Src antibodies (1:1000; \#2208; \#2101; Cell Signaling Technologies), anti-TRPV1 (1:2500; sc-12498; SCBT), and anti-alpha-tubulin (1:2500, T9026; Sigma Aldrich).

Four Independent Mouse Models of Cancer-Associated Pain {#sec5.2}
-------------------------------------------------------

All animal experiments were approved by the local governing board on animal protection laws (Regierungspräsidium) and were performed in accordance with their regulatory standards. All behavioral measurements were done in awake, unrestrained, age-matched adult (3 months old) male mice.(1)Osteolytic sarcoma model of cancer pain in the calcaneus bone: osteolytic sarcoma cells NCTC clone 2472 (National Collection of Type Cultures clone 2472; ATCC) (2 × 10^6^ per injection) were unilaterally injected into and around the calcaneus bone of C3H/HeNCrl mice ([@bib31]). Blocking antibodies, soluble VEGFR1 (sFlt1), anti-Flt1 peptide, or their respective controls were injected ipsilaterally intraplantar in the vicinity of the calcaneus bone. Antibodies against VEGFR1 (AF471; R&D Systems), VEGFR2 (AF644; R&D Systems), PLGF-2 (MAB465; R&D Systems), VEGF-B (AF590; R&D Systems), VEGF-A (AF-493-NA; R&D Systems) or normal goat IgG or rat IgG (AB-108-C, MAB006; R&D Systems) (each 5 μg diluted in 25 μl) were applied on days 1, 3, 5, 7, 9, 11, and 13 post-tumor implantation. An anti-Flt1 peptide, GNQWFI (25 μg diluted in 25 μl, RB-PP-0245; Ray Biotech), reverse peptide sequence, IFWQNG (25 μg diluted in 25 μl; Ray Biotech), soluble VEGFR1 (sFlt-1, SFC-M06; 10 μg diluted in 25 μl; Reliatech), or mouse IgG-Fc fragment (10 μg diluted in 25 μl, 4460-MG; R&D Systems) were administered every other day from days 1 to 13 post-tumor implantation.(2)Femur model of cancer-induced bone pain: Cells of the murine osteolytic breast carcinoma cell line, 4T1-Luc, which express the luciferase reporter gene ([@bib28]) or PBS (sham) were in mice of the Balb/c strain directly into the intermedullary space of the mouse femur following an arthrotomy (1.5 × 10^5^ cells/injection), as described previously ([@bib6]). Different cohorts of mice treated with MF-1 (ImClone Systems), DC101 (ImClone Systems), or control IgG (DivBioScience) were injected systemically (each 40 mg/kg body weight) every third day over 4 weeks post-tumor implantation ([@bib9; @bib13]).(3)In gene-targeted mice, we injected lung carcinoma cells of the ETCC clone 1642 (European Collection of Cell Cultures), isogenic with the C57Bl6 mouse strain, subcutaneously in the plantar and dorsal side of the mouse hind paw (7 × 10^5^ cells/injection) ([@bib11]).(4)Orthotopic injection model of PDAC: Mouse pancreatic carcinoma cells (PanCO2, 5000 cells resuspended in 5 μl) or PBS (sham) were injected into the pancreas of deeply anesthetized C57Bl6 mice ([@bib32]), keeping the abdominal surgical cut to a minimum. Abdominal sensitivity to graded von Frey stimuli was assessed in awake, freely moving mice, and withdrawal behavior was analyzed.

In all models, all behavioral analyses were performed in a blinded manner; i.e., the investigator was unaware of the experimental condition tested.

Ethics Statement for Human Tissues {#sec5.3}
----------------------------------

The use of archived pancreatic tissues was approved by the institutional review board, and written informed consent was obtained from the patients prior to the surgical procedure (ethics committee, University of Heidelberg; \#301/2001).

Additional details on experimental procedures are given in [Supplemental Information](#mmc1){ref-type="supplementary-material"}.
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Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S7Movie S1. Sham Operated, Related to Figure 8This depicts the nature and extent of nocifensive behavior and weight bearing in mice 30 days after sham surgery.Movie S2. Tumor Bearing IgG Injected, Related to Figure 8This depicts the nature and extent of nocifensive behavior, such as guarding of the tumor-bearing limb and lifting of the affected paw above the wire-mesh bottom, reduction in weight-bearing of the affected paw, sporadic hopping behavior during ambulation in tumor-bearing mice 30 days after implantation of breast cancer cells unilaterally in the femur bone cavity; in addition, the mouse shown in the video received intraperitoneal injections of control IgG.Movie S3. Tumor Bearing MF1 Injected, Related to Figure 8This depicts the nature and extent of nocifensive behavior in tumor-bearing mice 30 days after implantation of breast cancer cells unilaterally in the femur bone cavity; in addition, the mouse received intraperitoneal injections of an anti-VEGFR1 antibody (MF1 clone).Movie S4. Tumor Bearing DC101 Injected, Related to Figure 8This depicts the nature and extent of nocifensive behavior in tumor-bearing mice 30 days after implantation of breast cancer cells unilaterally in the femur bone cavity; in addition, the mouse received intraperitoneal injections of an anti-VEGFR2 antibody (DC101 clone).Document S2. Article plus Supplemental Information
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![Expression of VEGFR1 and VEGFR2 in Sensory Neurons and Nociceptive Sensitization by VEGF-A\
(A and B) Typical examples (A) and quantitative representation (B) of large- and small-diameter sensory neurons (arrows and arrowheads, respectively) showing co-labeling of anti-VEGFR1 or anti-VEGFR2 with markers for subtypes of sensory neurons in sections of mouse DRG (n = 32 sections analyzed from five mice).\
(C) Western blot analysis on mouse DRG or lysates of neuron-enriched DRG cultures.\
(D) Co-immunostaining of anti-VEGFR1 or anti-VEGFR2 with a marker for peripheral nerves (PGP9.5) in mouse paw skin biopsies.\
(E and F) Time course (E) and dose dependence (F) of modulation of mechanical sensitivity at the plantar surface of the hind paw following intraplantar application of VEGF-A. Shown in (F) is the integral of entire stimulus-response frequency curves (area under the curve \[AUC\]) to application of graded mechanical force (0.07--0.6 g) at different time points following administration of VEGF-A or saline in the hind paw (n = at least 4 mice per dose); an increase in the AUC is indicative of exaggerated pain sensitivity.\
(G and H) Time course (G) and dose dependence (H) of effects of intraplantar injection of VEGF-A or vehicle on paw withdrawal latency to noxious heat (n = at least 4 mice per dose).\
(I) Analysis of Evan's blue extravasation in mouse skin explants after cutaneous injection of PBS (vehicle), histamine (1 μg), or various doses of VEGF-A (1--10 ng).\
(J) Typical examples (upper traces) and summary (lower graph) of mean firing rates of mechanoreceptive nociceptors at 30 min after exposure to vehicle (PBS) or various doses of VEGF-A in the paw skin-saphenous nerve preparation (n = at least 10 fibers/dose). Negative control lacking primary antibodies and bright-field images of H&E staining showing tissue morphology in sections (not adjacent, but derived from the same animals as the immunostained sections) are shown in (A) and (D).\
^∗^p \< 0.05 as compared with basal, †p \< 0.05 as compared with corresponding data point for the vehicle group, ANOVA followed by post hoc Fisher's test. Data are presented as mean ± SEM. Scale bars represent 50 μm in (A) and (D). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Delineating VEGF Family Ligands and Their Receptors in Nociceptive Sensitization\
(A) Schematic representation of known ligand specificity and tools employed.\
(B) Effects of intraplantar delivery of neutralizing antibodies against VEGFR1 or VEGFR2 on intraplantar VEGF-A-induced mechanical hypersensitivity (left) and thermal hyperalgesia (right) (n = 8 mice/group).\
(C) Effects of a VEGFR1-neutralizing antibody on mechanoreceptive nociceptors in skin-nerve preparation (n = 8 fibers/group).\
(D) Effects of intraplantar injection VEGF-A (100 pg) in VEGFR1-Tk^−/−^ mice and WT controls (n = 8 mice/group).\
(E) Effects of intraplantar neutralizing antibodies against NRP1 or NRP2 on VEGF-A-induced mechanical hypersensitivity (left) or thermal hyperalgesia (right) (n = 6 mice/group).\
(F--H) Effects of intraplantar application of VEGF-E (F), VEGF-B (G), or PLGF-2 (H) on mechanical sensitivity in hind paw of mice (n = at least 4 mice per dose).\
^∗^p \< 0.05 as compared with vehicle in (D) and compared with basal in all other panels; ^†^p \< 0.05 as compared with corresponding control group; ANOVA followed by post hoc Fisher's test. Data are presented as mean ± SEM. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Signaling Pathways Underlying Nociceptive Sensitization by VEGF-A\
(A) A schematic overview of intracellular signaling mediators activated by VEGFRs (in oval symbols) and their respective pharmacological inhibitors in square boxes.\
(B) Western blots showing VEGF-A-induced phosphorylation of ERK1/2 in neuron-enriched cultured DRG neurons (n = 3 independent experiments).\
(C) Effects of hind-paw injection of pharmacological inhibitors on mechanical hypersensitivity (left) and thermal hypersensitivity (right) evoked by intraplantar injection of VEGF-A (1 ng). Shown are effects following single-dose intraplantar injection: L-NAME (18.5 nmoles, NOS inhibitor), U71322 (20 pmoles, PLCγ inhibitor), LY294002 (1 nmole, PI3K inhibitor), PP2 (200 pmoles, Src Kinase inhibitor), PD98059 (18.7 nmoles, MEK inhibitor), SB203580 (30 nmoles, p38 MAPK inhibitor), vehicle (1% DMSO).\
(D) Experiments comparing the above data with effects of intraplantar combinations of half-maximal doses of PLCγ inhibitor and anti-VEGFR1 antibody on VEGF-A-induced mechanical hypersensitivity to 0.4 g von Frey force (upper) and thermal hyperalgesia (lower).\
(E and F) Effects of VEGF-A (1 ng, intraplantar) in mice lacking *Prkg1* selectively in nociceptive neurons of the DRG (SNS-*Prkg1*^−*/*−^ mice; E) or in mice lacking *Trpv1* (*Trpv1*^−/−^ mice; F) (n = 6--8 mice/group).\
(G) Western blots on Src phosphorylation in DRG cultures (three independent experiments).\
(H) TRPV1 expression in membranes of distal branches of sciatic nerve in mice receiving intraplantar injections of VEGF-A or vehicle (n = 3 mice/group).\
(I) Effects of VEGF-A (1 ng, intraplantar) in mice lacking *Trpa1* (*Trpa1*^−/−^ mice) (n = 8 mice/group).\
^∗^p \< 0.05 as compared with basal value, ^†^p \< 0.05 as compared with corresponding control, ANOVA followed by post hoc Fisher's test. Data are presented as mean ± SEM. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Role of VEGFR1 in Cancer Pain following Osteolytic Sarcoma Cell Implantation in the Calcaneus Bone\
(A) Western blot analyses for VEGFR1 or VEGFR2 expression in ipsilateral L3--L4 DRG of tumor-bearing mice or sham-treated mice and their quantitative densitometric analysis (n = 3 independent experiments; ^∗^p = 0.02; Student's t test).\
(B) Typical examples and quantitative summary of VEGFR1 expression in PGP9.5-positive peripheral nerves overlying bone metastases in tumor-affected or sham hind paw (n = 6 mice/group). Negative controls for immunostaining and H&E-stained sections from same animals (not adjacent sections) are included to judge morphology. epi, epidermis; der, dermis.\
(C and D) Whole-mount images (C) or cryosection (D) of a DRG 3 weeks after injection of lentivirions expressing EGFP and shRNA.\
(E) Western blot analysis of VEGFR1 expression in L3--L4 DRGs injected ipsilaterally (ipsi) with lentivirions, using contralateral DRGs as control.\
(F--H) Tumor-induced mechanical hypersensitivity (F) and tumor-induced hypertrophy and sprouting of epidermal sensory nerves expressing the marker protein PGP9.5 (G and H) in mice injected with lenti-VEGFR1-shRNA as compared with lenti-non targeting shRNA in the DRG (n = 5 mice/group).\
^∗^p \< 0.05 as compared with sham in (B), (H) and compared with basal in (F); ^†^p \< 0.05 as compared with lenti-non-targeting control; ANOVA followed by post hoc Fisher's test. Scale bars represent 50 μm in (B), (D), and (G) and 250 μm in (C). Data are presented as mean ± SEM. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Role of VEGFR1 in Cancer Pain following Hind Paw Implantation of C57BL6-Isogenic Lewis Lung Carcinoma Cells\
(A) Western blot analysis on DRGs from SNS-*Vegfr1*^−/−^ and *Vegfr1*^*fl/fl*^ (control) mice.\
(B--G) Analysis of SNS-*Vegfr1*^−*/*−^ and *Vegfr1*^*fl/fl*^ mice (n = 6--8 mice/group) with respect to intraplantar VEGF-A-induced mechanical (B) and thermal hypersensitivity (C), tumor-associated hypersensitivity (D), tumor-induced hypertrophy and sprouting of PGP-9.5-immunoreactive sensory nerves (E and F), and tumor growth (G), including negative control for immunostaining and an H&E-stained section.\
(H and I) Tumor-induced mechanical hypersensitivity (H) and tumor growth (I) in VEGFR1-Tk^−/−^ and WT mice.\
^∗^p \< 0.05 as compared with sham in (F) and compared with basal in other panels, ANOVA followed post hoc Fisher's test; in (D) and (H), ANOVA for repeated-measures was performed; ^†^p \< 0.05 as compared with corresponding control group, ANOVA for random measures followed by post hoc Fisher's test. Scale bar represents 50 μm in (E). Data are presented as mean ± SEM.](gr5){#fig5}

![Role of VEGFR1 in Pain Associated with PDAC\
(A and B) Examples (A) and quantitative analyses (B) of nerves (arrows) showing anti-VEGFR1 immunoreactivity in PDAC biopsies from patients. Arrowheads indicate blood vessels. n = 21 sections analyzed from 13 biopsies.\
(C and D) Typical examples (C) and quantitative summary (D) of VEGFR1 expression in PGP9.5-positive nerves in human PDAC and pancreas of healthy donors (n = 95 sections from 30 patients and 7 donors).\
(E and F) Typical examples (E) and quantitative summary (F) of the relation between VEGFR1 immunoreactivity in human PDAC biopsies and subjective pain rating reported by the patients (n = 79 sections from 30 patients).\
(G) Western blot analysis of VEGFR1 expression in DRGs of mice with Advillin-Cre-mediated pan-DRG VEGFR1 deletion (Adv-*Vegfr1*^−*/*−^) and controls (*Vegfr1*^*fl/fl*^).\
(H) VEGF-A-induced mechanical hypersensitivity (left) and thermal hyperalgesia (right) in Adv-*Vegfr1*^−*/*−^ and *Vegfr1*^*fl/fl*^ mice (n = at least 4 mice/group).\
(I and J) Comparison of early post-operative pain (red arrow), tumor-associated hypersensitivity (blue arrow) to 0.008 g of abdominal von Frey application (I) and integral of responses to all von Frey forces tested (right) and tumor mass (J) between Adv-*Vegfr1*^−*/*−^ mice, SNS-*Vegfr1*^−*/*−^ mice, and *Vegfr1*^*fl/fl*^ mice (n = at least 8 mice/group).\
^∗^p \< 0.05, t test in (D) and (F). ^∗^p \< 0.05 as compared with basal in (H) and (I); ANOVA for repeated-measures followed post hoc Fisher's test; ^†^p \< 0.05 as compared with corresponding control group, ANOVA for random measures followed by post hoc Fisher's test. Scale bar represents 100 μm in (A) and (C) and 50 μm in (E). Data are presented as mean ± SEM. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Role of Diverse VEGFR1 Ligands and Sequestering Agents in Cancer Pain in the Calcaneus Osteolytic Sarcoma Implantation Model\
(A) ELISA-based analysis of VEGF-A and PLGF-2 in hind paw (n = 4 mice each).\
(B) Effects of intraplantar application of VEGF-A-sequestering antibody (upper), PLGF-2-sequestering antibody (lower), or control IgGs on tumor-induced mechanical hypersensitivity and tumor growth (n = at least 6 mice/group).\
(C) Effects of intraplantar application of soluble-VEGFR1 (sFlt1) or control protein on tumor-induced mechanical hypersensitivity and tumor size (n = 5--6 mice/group).\
(D) Typical example (left) and densitometric quantification (right) of tyrosine phosphorylation of VEGFR1 in mouse hind paw in sham or tumor-bearing mice and its modulation by local application of anti-Flt1 or reverse peptide 8 days post-tumor implantation (n = 3 mice/group).\
(E) Effects of intraplantar application of anti-Flt1 or reverse peptide on tumor-induced mechanical hypersensitivity and tumor growth (n = 6--8 mice).\
^∗^p \< 0.05, ANOVA followed post hoc Fisher's test as compared with basal, ANOVA of repeated-measures performed in (B), (C), and (E); ^†^p \< 0.05 as compared with corresponding control group and ^\#^p \< 0.01 as compared with reverse peptide in (D), ANOVA for random measures followed by post hoc Fisher's test. Data are presented as mean ± SEM. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}

![Effects of Local or Systemic Immunological Blockade of VEGFR1 or VEGFR2 on Cancer Pain\
(A and B) Effects of a regime of local, intraplantar injections of either IgG or anti-VEGFR1 or anti-VEGFR2 antibodies (5 μg/dose) on tumor-induced mechanical hypersensitivity (A) and tumor-induced hypertrophy and sprouting of PGP9.5-immunoreactive epidermal sensory nerves (B) in the calcaneus osteolytic sarcoma implantation model (n = at least 6 mice/group).\
(C--E) Analysis of tumor-induced mechanical hypersensitivity in the ipsilateral mouse paw (C), spontaneous pain (D), and sprouting of the femur periosteal peptidergic nociceptive fibers (E) induced by implantation of mammary cancer cells in the mouse femur bone in mice receiving a regime of systemic injections of either control IgG or the VEGFR1-neutralizing MF-1 clone or the VEGFR2-neutralizing DC101 clone (40 mg/kg body weight per injection, n = 8 mice/group).\
In all panels, ^∗^p \< 0.05 as compared with basal; ANOVA of repeated-measures, ^†^p \< 0.05 as compared with control IgG, ^\#^p \< 0.01 as compared with sham; only in (D), p \< 0.05 between MF-1 and DC101 groups is indicated by \$ sign; ANOVA followed by post hoc Fisher's test. Scale bars represent 50 μm and 25 μm in (B) and (E), respectively. Data are presented as mean ± SEM. See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Movies S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}.](gr8){#fig8}

[^1]: Present address: Institute of Physiology and Medicine, Jobu University, 270-1 Shinmachi, Takasaki, Gunma 370-1393, Japan
